{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"EVEREST","nct_id":"NCT01120249","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=everest-nct01120249. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"S0931","arms":[{"description":"Patients receive oral everolimus once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm I","type":"EXPERIMENTAL"},{"description":"Patients receive oral placebo once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm II","type":"PLACEBO_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2025-09-01","type":"ACTUAL"},"conditions":["Kidney Cancer"],"enrollment":{"count":1545,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"everolimus","otherNames":[],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"OTHER"}],"last_update":"2025-09-16","lead_sponsor":"SWOG Cancer Research Network","official_title":"EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-07-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"5-year Recurrence-free Survival (RFS)","timeFrame":"5 years from registration"}],"references":[{"citation":"Gulati S, Tangen C, Ryan CW, Vaishampayan UN, Shuch BM, Barata PC, Pruthi DK, Bergerot CD, Tripathi A, Lerner SP, Thompson IM Jr, Lara PN Jr, Pal SK. Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Aug 1;7(8):e2425288. doi: 10.1001/jamanetworkopen.2024.25288.","pmid":"39106067","type":"DERIVED"},{"citation":"Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM Jr, Lara PN Jr. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2023 Sep 23;402(10407):1043-1051. doi: 10.1016/S0140-6736(23)00913-3. Epub 2023 Jul 28.","pmid":"37524096","type":"DERIVED"}],"start_date":{"date":"2011-04-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery","url":"https://clinicaltrials.gov/study/NCT01120249"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/everest-nct01120249"}